Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Short term Debt (2021 - 2023)

Historic Short term Debt for Alaunos Therapeutics (TCRT) over the last 3 years, with Q1 2023 value amounting to $11.0 million.

  • Alaunos Therapeutics' Short term Debt fell 2147.5% to $11.0 million in Q1 2023 from the same period last year, while for Mar 2023 it was $11.0 million, marking a year-over-year decrease of 2147.5%. This contributed to the annual value of $16.8 million for FY2022, which is 11307.83% up from last year.
  • According to the latest figures from Q1 2023, Alaunos Therapeutics' Short term Debt is $11.0 million, which was down 2147.5% from $16.8 million recorded in Q4 2022.
  • Over the past 5 years, Alaunos Therapeutics' Short term Debt peaked at $22.7 million during Q3 2022, and registered a low of $7.9 million during Q4 2021.
  • Over the past 3 years, Alaunos Therapeutics' median Short term Debt value was $14.0 million (recorded in 2022), while the average stood at $14.9 million.
  • As far as peak fluctuations go, Alaunos Therapeutics' Short term Debt skyrocketed by 11307.83% in 2022, and later crashed by 2147.5% in 2023.
  • Over the past 3 years, Alaunos Therapeutics' Short term Debt (Quarter) stood at $7.9 million in 2021, then surged by 113.08% to $16.8 million in 2022, then crashed by 34.46% to $11.0 million in 2023.
  • Its last three reported values are $11.0 million in Q1 2023, $16.8 million for Q4 2022, and $22.7 million during Q3 2022.